Adalimumab News and Research

RSS

Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.

New Crohn's disease treatment Humira promises to reduce symptoms

The Food and Drug Administration (FDA) in the United States has given it's approval for the use of the drug Humira (adalimumab) to treat adults suffering from Crohn's disease.

28 Feb 2007

FDA approves Humira (adalimumab) for Crohn's disease

The U.S. Food and Drug Administration (FDA) today approved Humira (adalimumab) to treat adult patients with moderately to severely active Crohn's disease, a chronic inflammatory disease of the intestines, which affects an estimated one million Americans.

27 Feb 2007

Arthritis drugs not as risky as first thought

Researchers now say that two biotech drugs used to treat rheumatoid arthritis, Humira (Abbott Laboratories) and Remicade (Johnson & Johnson), may not raise the risk of cancer and infections as much as was initially feared.

8 Nov 2006

Tumor necrosis factor A antagonist use and cancer in patients with rheumatoid arthritis

Patients with rheumatoid arthritis (RA), an autoimmune, inflammatory disease marked by progressive joint and organ damage, face a high risk of developing cancer.

31 Aug 2006

New rheumatoid arthritis drugs may put patients at risk of infections and cancer

Anti-TNF (tumor necrosis factor) therapies are a tried and tested type of medication used for treating rheumatoid arthritis and the drugs provide benefit to many of thousands of patients worldwide.

21 May 2006

Study shows strong association between treatment with TNF-blocking antibodies and development of serious infections

A new meta-analysis of many previous studies of TNF- (tumor necrosis factor) blocking antibodies for treatment of rheumatoid arthritis has confirmed a previously discovered increased risk for serious infection and has found that cancer also is a potential risk associated with the drugs.

17 May 2006

Evidence supports combination therapy for achieving remission of early rheumatoid arthritis

A chronic and potentially crippling inflammatory disorder, rheumatoid arthritis (RA) progressively wears away the cartilage and bone.

8 Jan 2006

Adalimumab and methotrexate is about five times more effective than methotrexate alone for rheumatoid arthritis

For people with long-standing rheumatoid arthritis, combined treatment with the new "biologic" drug adalimumab and methotrexate is about five times more effective than methotrexate alone, according to a new systematic review of studies.

15 Aug 2005

Abbott receives European approval to market Humira

Abbott has announced that it has received approval from the European Commission to market Humira (adalimumab) as a treatment for psoriatic arthritis and early rheumatoid arthritis (RA) in Europe.

15 Aug 2005

Biologic treatments to treat the physical symptoms of psoriasis

More than 4.5 million adults in the United States have been diagnosed with psoriasis and 21 percent of those have moderate to severe psoriasis. This chronic condition, characterized by thick, red, scaly plaques that itch and bleed, not only makes the activities of daily life difficult, but also can affect a person's emotional well being.

21 Jul 2005

Tumour Necrosis Factor alpha (TNF-alpha) blocking agents cause skin disease

Members of the second most important family of drugs used to treat rheumatoid arthritis can cause serious dermatological conditions in a quarter of patients under treatment, reveals a study published in the journal Arthritis Research and Therapy.

3 Apr 2005

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004

FDA approves new drug Enbrel for psoriasis

The U.S. Food and Drug Administration has approved the biologic drug etanercept (brand name Enbrel) to treat chronic, moderate to severe plaque psoriasis in adults.

1 May 2004